Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reena Philip

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or FusionsDiana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast CancerJennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Clinical Chemistry|December 17, 2009
Protein-based multiplex assays: mock presubmissions to the US Food and Drug AdministrationFred E Regnier, Steven J Skates, Mehdi Mesri, et al.
The Oncologist|November 4, 2020
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S Anscher, Elaine Chang, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsElizabeth S Duke, Liza Stapleford, Nicole Drezner, et al.
JCO Precision Oncology|November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker SummitDaniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or FusionsDiana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2020
FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast CancerJennifer J Gao, Christy L Osgood, Yutao Gong, et al.
Clinical Chemistry|December 17, 2009
Protein-based multiplex assays: mock presubmissions to the US Food and Drug AdministrationFred E Regnier, Steven J Skates, Mehdi Mesri, et al.
The Oncologist|November 4, 2020
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S Anscher, Elaine Chang, Xin Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsElizabeth S Duke, Liza Stapleford, Nicole Drezner, et al.
JCO Precision Oncology|November 29, 2022
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker SummitDaniel F Hayes, Roy S Herbst, Jonathan L Myles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or AlterationsLuckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based ChemotherapyGwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, et al.
Pageof 6